Lee T Zane
Overview
Explore the profile of Lee T Zane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simpson E, Paller A, Boguniewicz M, Eichenfield L, Feldman S, Silverberg J, et al.
Dermatol Ther (Heidelb)
. 2018 Oct;
8(4):605-619.
PMID: 30345457
Introduction: The impact of crisaborole ointment, a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis (AD), on quality of life (QoL) was assessed in two...
2.
Yosipovitch G, Gold L, Lebwohl M, Silverberg J, Tallman A, Zane L
Acta Derm Venereol
. 2018 Jan;
98(5):484-489.
PMID: 29363715
Pruritus occurs in all patients with atopic dermatitis and requires quick relief to reduce disease exacerbation and improve quality of life. Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for...
3.
Rich P, Vlahovic T, Joseph W, Zane L, Hall S, Gellings Lowe N, et al.
Cutis
. 2017 Nov;
100(4):259-264.
PMID: 29136060
There currently are 3 topical agents approved by the US Food and Drug Administration (FDA) to treat onychomycosis: tavaborole, efinaconazole, and ciclopirox. The phase 3 clinical trial designs for these...
4.
Aly R, Gupta A, Winter T, Zane L, Vlahovic T
J Drugs Dermatol
. 2017 Oct;
16(10):1016-1021.
PMID: 29036255
Toenail onychomycosis is a chronic fungal infection that often requires prolonged treatment in order to effectively manage pathogenic organisms and obtain a clear nail. Traditionally, certain clinical features of onychomycosis,...
5.
Eichenfield L, Call R, Forsha D, Fowler Jr J, Hebert A, Spellman M, et al.
J Am Acad Dermatol
. 2017 Aug;
77(4):641-649.e5.
PMID: 28823881
Background: Long-term topical treatment is often required for atopic dermatitis (AD), a chronic inflammatory skin disease. Objective: To assess the long-term safety results from a multicenter, open-label, 48-week safety study...
6.
Gupta A, Hall S, Zane L, Lipner S, Rich P
J Dermatolog Treat
. 2017 May;
29(1):44-48.
PMID: 28521541
Purpose: The role of topical antifungal agents in the long-term management of toenail onychomycosis is not well established. The current study evaluated durability of clinical benefit of tavaborole topical solution,...
7.
Paller A, Tom W, Lebwohl M, Blumenthal R, Boguniewicz M, Call R, et al.
J Am Acad Dermatol
. 2016 Jul;
75(3):494-503.e6.
PMID: 27417017
Background: Additional topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks. Objective: We sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase...
8.
Zane L, Hughes M, Shakib S
Am J Clin Dermatol
. 2016 Jun;
17(5):519-526.
PMID: 27335049
Background: Inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis often present in sensitive and thin-skinned areas that are at higher risk for topical treatment-related skin irritation (e.g., burning,...
9.
Zane L, Kircik L, Call R, Tschen E, Draelos Z, Chanda S, et al.
Pediatr Dermatol
. 2016 May;
33(4):380-7.
PMID: 27193740
Background: Phosphodiesterase-4 (PDE4) is a promising target in atopic dermatitis (AD) treatment. The pharmacokinetics (PK), safety, and efficacy of crisaborole topical ointment, 2% (formerly AN2728) (Anacor Pharmaceuticals, Palo Alto, CA),...
10.
Zane L, Chanda S, Coronado D, Del Rosso J
Dermatol Online J
. 2016 May;
22(3).
PMID: 27136621
Onychomycosis is a common and difficult-to-treat fungal infection of the nail unit that gradually leads to dystrophic changes of the nail plate and nail bed. If untreated, infection progresses and...